| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
4-Bromo-2-hydroxybenzaldehyde does not have a specific biological target itself. It is a synthetic intermediate used to prepare bioactive compounds. Derivatives of this compound inhibit GABA-T and SSADH, enzymes involved in GABA metabolism. Inhibition of GABA-T increases GABA levels in the brain, while inhibition of SSADH affects the GABA shunt pathway. These activities suggest potential applications in neurological disorders.
|
|---|---|
| ln Vitro |
It is a crucial starting point and intermediate for the production of organic synthesis, pharmaceuticals, agricultural compounds, and colors.
In vitro, derivatives of 4-bromo-2-hydroxybenzaldehyde have shown competitive inhibition of GABA-T and SSADH. This inhibition suggests potential use in designing drugs for conditions related to the GABAergic system, such as epilepsy, anxiety, and sleep disorders. The parent compound is used as a synthetic intermediate for these derivatives. |
| ln Vivo |
In vivo data for 4-bromo-2-hydroxybenzaldehyde are limited as it is a chemical intermediate. Drug candidates synthesized from this compound, such as γ-secretase modulators, may be evaluated in animal models for neurological or other indications. The compound itself is not administered to animals as a test compound.
|
| Enzyme Assay |
4-Bromo-2-hydroxybenzaldehyde is not typically used in cell-free enzyme/receptor binding assays. Its role is as a synthetic intermediate. For compounds synthesized using this reagent, typical binding assays may be performed. These involve incubating the test compound with purified enzymes (e.g., GABA-T, SSADH) in buffered solutions, with enzyme activity measured spectrophotometrically.
|
| Cell Assay |
Cell-based assays are not directly performed on 4-bromo-2-hydroxybenzaldehyde due to its lack of biological activity. However, drug candidates synthesized from this intermediate may be tested in cellular systems. For GABAergic compounds, neuronal cell lines or primary neurons are cultured and treated with the synthesized compound. GABA levels, neuronal activity, and cell viability are assessed.
|
| Animal Protocol |
In vivo animal studies are not conducted with 4-bromo-2-hydroxybenzaldehyde itself, as it is a chemical reagent. Drug candidates synthesized from this intermediate may be evaluated in animal models for efficacy, pharmacokinetics, and toxicity. For γ-secretase modulators, animal models of Alzheimer's disease or other indications may be used. All procedures follow institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
4-Bromo-2-hydroxybenzaldehyde is a synthetic chemical intermediate and is not subject to pharmacokinetic evaluation as a drug. Its physicochemical properties include a molecular weight of approximately 197 g/mol and a molecular formula of C7H5BrO2. The compound is stable under normal storage conditions and is available as an off-white crystalline powder.
|
| Toxicity/Toxicokinetics |
The toxicological profile of 4-bromo-2-hydroxybenzaldehyde has not been extensively characterized. As a brominated aromatic aldehyde, it may cause skin, eye, and respiratory tract irritation. Standard laboratory safety precautions should be observed, including the use of personal protective equipment (gloves, goggles, lab coat) and adequate ventilation. Ingestion or inhalation should be avoided.
|
| Additional Infomation |
4-Bromo-2-hydroxybenzaldehyde is not a drug but a valuable chemical intermediate for pharmaceutical synthesis. It is used in the synthesis of BIIB042, a γ-secretase modulator. Derivatives of this compound inhibit GABA-T and SSADH, suggesting potential applications in epilepsy, anxiety, and sleep disorders. It is also used in the synthesis of azides. It is not approved for clinical use.
|
| Molecular Formula |
C7H5BRO2
|
|---|---|
| Molecular Weight |
201.02
|
| Exact Mass |
199.947
|
| CAS # |
22532-62-3
|
| PubChem CID |
4066019
|
| Appearance |
Yellow to brown solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
256.2±25.0 °C at 760 mmHg
|
| Melting Point |
50-54ºC
|
| Flash Point |
108.8±23.2 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.657
|
| LogP |
2.92
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
127
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=C(C=C1Br)O)C=O
|
| InChi Key |
HXTWKHXDFATMSP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H5BrO2/c8-6-2-1-5(4-9)7(10)3-6/h1-4,10H
|
| Chemical Name |
4-bromo-2-hydroxybenzaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~497.5 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (12.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9746 mL | 24.8731 mL | 49.7463 mL | |
| 5 mM | 0.9949 mL | 4.9746 mL | 9.9493 mL | |
| 10 mM | 0.4975 mL | 2.4873 mL | 4.9746 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
